Antifungal Dermatologic Agents: Azoles and Allyiamines

Compendium on Continuing Education for the Practicing Veterinarian

Volumn 22, Issue 6, 2000, Pages 548-559

  De Jaham, Caroline ^a,d   Paradis, Manon ^b   Papich, Mark G ^c  

^a Centre Vétérinaire DMV   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

^d DMV Veterinary Center   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0346976188     PISSN: 01931903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Woolley DW: Some biological effects produced by benzimidazole and their reversal by purines. J Biol Chem 152:225-232, 1944.
2. Godefroi EF, Heeres J, Van Custem J, et al: The preparation and antimycotic properties of derivative of 1-phenylethylim-idazole. J Med Chem 12:784-791, 1969.
3. Legendre AM, Gompf R, Bone D: Treatment of feline cryptococcosis with ketoconazole. JAVMA 181:1541-1542, 1982.
4. Malik R, Wigney DI, Muir DB, et al: Cryptococcosis in cats: Clinical and mycological assessment of 29 cases and evaluation of treatment using orally administered fluconazole. J Med Vet Mycol 30:133-144, 1992.
5. Moriello KM, DeBoer DJ: Efficacy of griseofulvin and itraconazole in the treatment of experimentally induced dermatophytosis in cats. JAVMA 207:439-444, 1995.
6. Heit MC, Riviere JE: Antifungal therapy: Ketoconazole and other azole derivatives. Compend Contin Educ Pract Vet 17(1):21-31, 1995.
7. Medleau L, Gilbert JJ, Marks MA: Itraconazole for the treatment of cryptococcosis in cats. J Vet Intern Med 9:39-42, 1995.
8. Greek JS: Update on dermatologic therapy. Vet Med (Nov): 1021-1024, 1996.
9. Papich MG: Antifungal drugs. Proc Annu Members Meet Am Acad Vet Dermatol Am Coll Vet Dermatol:4-9, 1997.
10. Sud IJ, Feingold DS: Mechanisms of action of the antimycotic imidazoles. J Invest Dermatol 76:438-441, 1982.
11. Willard MD, Nachreiner R, McDonald R, Roudebush P: Ketoconazole-induced changes in selected canine hormone concentrations. Am J Vet Res 47:2504-2509, 1986.
12. Gupta AK, Sauder DN, Shear NH: Antifungal agents: An overview. Part I. J Am Acad Dermatol 30:677-698, 1994.
13. Artis WM: Final pathway for delivery of oral antifungals to keratinized cornified skin, in Oral Therapy in Dermatoses: A Step Forward. Oxford, The Medicine Publishing Foundation, 1985, pp 61-70.
14. Moriello KA: Ketoconazole: Clinical pharmacology and therapeutic recommendations. JAVMA 188:303-306, 1986.
15. Medleau L, Chalmers SA: Ketoconazole for treatment of dermatophytosis in cats. JAVMA 200:77-78, 1992.
16. Dunbar M, Lee Pyle R, Boring JG, McCoy CP: Treatment of canine blastomycosis with ketoconazole. JAVMA 182: 156-157, 1983.
17. Noxon JO, Diglio K, Schmidt DA: Disseminated histoplasmosis in a cat: Successful treatment with ketoconazole. JAVMA 181:817-819, 1982.
18. Greene CE: Antifungal chemotherapy, in Greene CE (ed): Infections Diseases of Dogs and Cats. Philadelphia, WB Saunders Co, 1989, pp 649-658.
19. Noxon JO, Monroe WE, Chinn DR: Ketoconazole therapy in canine and feline cryptococcosis. JAAHA 22:179-183, 1986.
20. Werner AH, Werner BE: Feline sporotrichosis. Compend Contin Ednc Pract Vet 15(9):1189-1198, 1993.
21. Sharp NJH, Sullivan M: Use of ketoconazole in treatment of canine nasal aspergillosis. JAVMA 194:782-784, 1989.
22. Scott DW, Miller WH Jr, Griffin CE: Fungal skin diseases, in Scott DW, Miller WH Jr, Griffin CE (eds): Small Animal Dermatology, ed 5. Philadelphia, WB Saunders Co, 1995, pp 329-391.
23. DeBoer DJ, Moriello KM, Cairns R: Clinical update on feline dermatophytosis - Part II. Compend Contin Ednc Pract Vet 17(12):1471-1480, 1995.
24. Willard MD, Nachreiner R, Howard VC: Effect of long-term administration of ketoconazole in cats. Am J Vet Res 47:2510-2513, 1986.
25. Van Cauteren H, Lampo A, Vanderberghe J, et al: Toxicological profile and safety evaluation of antifungal azole derivatives. Mycoses 32:60-66, 1989.
26. da Costa PD, Merideth RE, Sigler RL: Cataracts in dogs after long-term ketoconazole therapy. Vet Comp Ophthalmol 6:176-180, 1996.
27. Zürcher RM, Frey BM, Frey FJ: Impact of ketoconazole on the metabolism of prednisolone. Clin Pharmacol Ther 45: 366-372, 1989.
28. Gupta AK, Sauder DN, Shear NH: Antifungal agents: An overview. Part II. J Am Acad Dermatol 30: 911-933, 1994.
29. Boothe DM, Herring I, Calvin J, Way N, Dvorak J: Itraconazole disposition after single oral and intravenous and multiple oral dosing in healthy cats. Am J Vet Res 58:872-877; 1997.
30. Heykants J, Michiel M, Meuldermans W, et al: The pharmacokinetics of itraconazole in animals and man: An overview, in Fromtling RA (ed): Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. Barcelona, JR Prous Science Publisher, 1987, pp 223-249.
31. Van Cauteren, Heykants J, DeCostner R, et al: Itraconazole: Pharmacologic studies in animals and humans. Rev Infect Dis 9:S43-S46, 1987.
32. Medleau L, Rakich PM: Microsporum canis pseudomycetomas in a cat. JAAHA 30:573-576, 1994.
33. Legendre AM, Rohrbach BW, Toal RL, et al: Treatment of blastomycosis with itraconazole in 112 dogs. J Vet Intern Med 10:365-371, 1996.
34. Peaston A: Sporotrichosis. J Vet Intern Med 7:44-45, 1993.
35. Legendre AM: Antimycotic drug therapy, in Bonagura JD Kirk RW (eds): Current Veterinary Therapy XII. Philadelphia, WB Saunders Co, 1995, pp 327-331.
36. Simons EG: Pheohyphomycosis in a cat caused by Alternaria infectoria. Mycoses 36:451-454, 1993.
37. Michaud AJ: Pheaohyphomycotic rhinitis due to Exophiala jeanselmei in a domestic cat. Feline Pract 21:19-21, 1993.
38. Hodges RD, Legendre AM, Adams LG, et al: Itraconazole for the treatment of histoplasmosis in cats. J Vet Intern Med 8:409-423, 1994.
39. Medleau L, Greene CE, Rakich PM: Evaluation of ketoconazole and itraconazole for treatment of disseminated cryptococcosis in cats. Am J Vet Res 41:1454-1458, 1990.
40. Brooks DE, Legendre AM, Gum GG, et al: The treatment of canine ocular blastomycosis with systemically administered itraconazole. Prog Vet Comp Ophthalmol 4:262-268, 1991.
41. Manciati F, Pedonese F, Zullino C: Efficacy of oral administration of itraconazole to cats with dermatophytosis caused by Microsporum canis. JAVMA 213:993-995, 1998.
42. Martin S: Pharm profile: Itraconazole. Compend Contin Educ Pract Vet 21(2):145-147, 1999.
43. Hill B, Moriello KA, Shaw SE: A review of systemic antifungal agents. Vet Dermatol 6:59-66, 1995.
44. Gupta AK, Sibbald GR, Lynde CW, et al: Onychomycosis in children: Prevalence and treatment strategies. J Am Acad Dermatol 36:395-402, 1997.
45. Plotnick AN, Boshoven EW, Rosychuk RAW: Primary cutaneous coccidioidomycosis and subsequent drug eruption to itraconazole in a dog. JAAHA 33:139-143, 1997.
46. Dudley MN: Clinical pharmacology of fluconazole. Pharmacotherapy 6:141-145, 1990.
47. Humphrey MJ, Jevons S, Tarbit MH: Pharmacokinetics evaluation of UK-49858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother 28:648-653, 1985.
48. Vaden SL, Heit MC, Hawkins EC, et al: Fluconazole in cats: Pharmacokinetics following intravenous and oral administration and penetration into cerebrospinal fluid, aqueous humor and pulmonary epithelial lining fluid. J Vet Pharmacol Therap 20:181-186, 1997.
49. Haneke E: Fluconazole levels in human epidermis and blister fluids. Br J Dermatol 123:273-277, 1990.
50. Sharp NJH, Harvey CE, O'Brien JA: Treatment of canine nasal aspergillosis/penicillinosis with fluconazole. J Small Anim Pract 32:513-516, 1991.
51. Grant SM, Clissold SP: Fluconazole: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 39: 877-917, 1990.
52. Thienpont D, Van Cutsem J, Van Cauteren H, Marsboom R: The biological and toxicological properties of imazalil Drug Res 31:309-315, 1981.
53. Van Gestel J, Van Cutsem J, Thienpont D: Vapor phase activity of imazalil. Chemotherapy 27:270-276, 1981.
54. Sharp NJH: Nasal aspergillosis, in Kirk RW (ed): Current Veterinary Therapy X. Philadelphia, WB Saunders Co, 1989, pp 1106-1109.
55. Bussieras J, Chermette R, Bourdeau P: Le traitement des teignes des carnivores au moyen des dérivés récents de l'imidazole. Prat Méd Chirurg Anim Cie 19:152-154, 1984.
56. Carlotti D, Couprie B: Dermatophyties du chien et du chat: Actualités. Prat Méd Chirurg Animal Cie 23:449-457, 1988.
57. de Jaham C, Paradis M: La dermatophytie feline II: Modalites thérapeutiques. Med Vet Qué 27:147-152, 1997.
58. Guillot J, Chermette R, Maillard R: Les candidoses des carnivores domestiques: Actualisation a propos de 10 cas. Point Vet 28:51-60, 1996.
59. Mason KV: Cutaneous Malassezia, in Griffin CE, Kwochka KW, McDonald JM (eds): Current Veterinary Dermatology. St. Louis, Mosby, 1993, pp 44-48.
60. de Jaham C, Pagé N, Lambert AJ, Paradis M: Enilconazole emulsion in the treatment of dermatophytosis in Persian cats, in Kwochka KW, Willemse T, Von Tscharner C (eds): Adv Vet Dermatol ed 3, 1998, pp 299-307.
61. Cornelissen F, Van den Bossche H: Synergism of the antimicrobial agents miconazole, bacitracin and polymyxin B. Chemotherapy 29:419-427, 1983.
62. Ryder NS: Terbinafine: Mode of action and properties of the sqalene epoxidase inhibition. Br J Dermatol 126:2-7, 1992.
63. Feargemann J, Zehender H, Jones T, et al: Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum and eccrine sweat during and after 250 mg terbinafine orally once per day in man. J Invest Dermatol 24:525-528, 1990.
64. Balfour JA, Faulds D: Terbinafine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 43:259-284, 1992.
65. Jones TC: Overview of the use of terbinafine (Lamisil) in children. Br J Dermatol 132:683-689, 1995.
66. Sparkes AH: Terbinafine in cats: A pharmacokinetic study. Proc Third World Cong Vet Dermatol Edinburgh, Scotland, UK, 1996.
67. Carlotti DN: Dermatophytosis part 2 - diagnosis and therapy. Proc Third World Cong Vet Dermatol Edinburgh, Scotland, UK, 1996, pp 37-43.
68. Shear NH, Villars V, Marsolais C: Terbinafine: An oral and topical antifungal agent. Clin Dermatol 9:487-495, 1991.